A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 21 May 2018
At a glance
- Drugs Cytarabine (Primary) ; Ibrutinib (Primary) ; Idarubicin (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 05 Dec 2017 Status changed from recruiting to discontinued.
- 24 Aug 2017 Status changed from suspended to recruiting.
- 24 Apr 2017 Status changed from recruiting to suspended due to Regulatory.